This was the central question that experts debated at a special CAN-SG webinar earlier this week (16th Sept) and their answer was a resounding ‘no’. They agreed that the government’s plan to run a clinical trial on children with gender distress to determine whether puberty blockers (PBs) are safe raises too many ethical and methodological problems […]
Tag: Puberty Blockers
This article by Dr David Bell and Dr Sinead Helyar examines concerns regarding a proposed clinical trial of puberty blockers (PBs) for children with gender dysphoria. It argues that a PB trial would pose unacceptable risks and contravene ethical standards. The authors advocate alternative avenues for research and safer treatment methods for this vulnerable group of children.
Categories
Conference 2024
First Do No Harm Critical perspectives on sex and gender in healthcare With over 150 attendees, and hundreds from across the world joining the livestream, #FirstDoNoHarm was a resounding success. The sold-out event platformed and hosted clinicians and patients from around the UK, Europe and the US. In the media THE BMJ I The Telegraph […]
The review of the literature found that no well-designed studies have ever been conducted to properly assess the impact of puberty blockers on cognitive function.
Our current understanding of the importance of puberty in the development of cognitive function, animal studies and very limited data from human studies do not support the notion that puberty blockers have no impact on cognitive development or that any effects are reversible.
Indeed, the evidence to date points in the other direction.
BREAKING Extended deadline for feedback on development of a WHO guideline on the health of trans and gender diverse people. Submissions now close 2 Feb 2024 In June 2023, the World Health Organisation (WHO) announced it was planning to develop a guideline on the health of trans and gender diverse people; a further notice on 18 December […]